De-escalating radiotherapy in pathologic complete response oral cancer after neoadjuvant immunochemotherapy: equal survival, better life, and a biomarker guide
Adjuvant radiotherapy omission with maintenance immunotherapy appears to be a safe and patient-beneficial strategy for OSCC patients achieving pCR after NICT. The integrated TP53/B-cell biomarker model provides preliminary evidence for personalizing this de-escalation approach.
Authors
- Zhenjie Guan
- Qiongqiong Yu
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.3389/fonc.2026.1761516
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00